Sonazoid CEUS for Early HCC Surveillance
Key facts
- Where
- Tianjin, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07590284, who can take part
Where in China
- Tianjin Third Central HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tianjin Third Central Hospital
- Trial code
- NCT07590284
- Record updated
- 15 May 2026
- Original description
This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT/CEMRI every 12 months.Read full original descriptionShow less
A Multicenter, Prospective Study of Sonazoid CEUS for Early HCC Surveillance in a High-risk Population
This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT/CEMRI every 12 months.
Inclusion: Cirrhotic patients diagnosed clinically or radiologically due to any etiology (patients with cirrhosis due to congenital fibrosis and patients with cirrhosis due to vascular causes were excluded); Age 18-80 years old; Able to receive regular imaging, including US, CEUS, and CECT or CEMRI or EOB-MRI, according to the diagnostic and treatment procedures; Obtained informed consent from the patient.
Exclusion: Patients with known hypersensitivity to enhanced imaging contrast agents; Patients with severe cardiac, pulmonary or renal insufficiency that precludes CECT or CEMRI or EOB-MRI; Patients with egg or egg-product allergy, or with severe right-to-left cardiac shunt or intrapulmonary shunt; Patients with pathologic or enhanced imaging of established HCC who have not undergone curative treatment; Lactating and pregnant women; Those who are not suitable for enrollment as assessed by the investigator.